drug_type
RELEVANT_DRUG
intervention_type
Cell therapy
drug_description
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting CEA (CEACAM5) and infused intravenously to mediate antigen-specific tumor cell killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor specific for CEA (CEACAM5). CAR binding to CEA activates the T cells to release cytotoxic effector molecules and cytokines, mediating MHC-independent tumor cell killing.
drug_name
CEA-targeted CAR-T cells (C-13-60)
nct_id_drug_ref
NCT06043466